Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Monolithic Power Systems Inc (MPWR) Price & Performance

Mesoblast LimitedTrade
Monolithic Power Systems IncTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Monolithic Power Systems Inc — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Monolithic Power Systems Inc trades at $1,433.02 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 31.2× Mesoblast Limited's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOMPWR
Market Cap
$2.21B$68.90B
Sector
TechnologyUtilities
52-Week High
$20.96$1.69K
52-Week Low
$12.88$820.74
Enterprise Value
$2.21B$67.51B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Monolithic Power Systems Inc

MPWR is trading at $1,446.91, up 4.77% in the last 24 hours, with a bullish technical signal and strong earnings momentum after beating Q2 2026 estimates. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, though valuation ratios like P/E of 85.55 are elevated. Recent news highlights AI-driven revenue growth and a legal investigation into potential misleading statements.

The outlook is positive with an 88% analyst buy rating and a $1,870 consensus price target, but risks include high valuation sensitivity, competitive pressures, and legal scrutiny. Earnings growth from AI infrastructure demand remains a key catalyst for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR